Method for Producing Significant Amounts of B19 Virus for Development of Killed or Attenuated Vaccines
Posted Jan 17 2012 7:00pm
Description of Invention: Human parvovirus B19 (B19) is a common infection of children and adults and is the cause of fifth disease. B19 selectively infects erythroid progenitor cells of bone marrow, fetal liver and a small number of specialized cell lines. These specific cell lines demonstrate limited infectibility and commonly produce little or no virus following initial inoculation with B19. Current methods for producing infectious B19 require phlebotomy of infrequently available infected donors. The available technology describes a method of producing pure populations of human erythroid progenitor cells that are fully permissive to B19 infection. The ability to efficiently generate significant amounts of infectious B19V in cells is useful for the development of killed or attenuated vaccines, therapeutics and efficient diagnostic tools for prevention and treatment of B19V.
Applications:
Human parvovirus B19 diagnostic
Vaccine manufacture
Research and development of anti-parvovirus agents
Advantages: Method produces pure populations of human erythroid progenitor cells that are fully permissive of B19 infection
Development Status:
Pre-clinical
In vitro data available
Inventors: Susan Wong (NHLBI) Neal S Young (NHLBI)
Collaborative Research Opportunity: The NHLBI Hematology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize novel methods to produce parvovirus B19 and use as diagnostic or vaccine. Please contact Dr. Neal Young at 301-496-5093, YoungNS@mail.nih.gov for more information.
For Licensing Information Please Contact: Kevin Chang Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: changke@mail.nih.gov Phone: 301-435-5018 Fax: 301-402-0220
Description of Invention:
Human parvovirus B19 (B19) is a common infection of children and adults and is the cause of fifth disease. B19 selectively infects erythroid progenitor cells of bone marrow, fetal liver and a small number of specialized cell lines. These specific cell lines demonstrate limited infectibility and commonly produce little or no virus following initial inoculation with B19. Current methods for producing infectious B19 require phlebotomy of infrequently available infected donors. The available technology describes a method of producing pure populations of human erythroid progenitor cells that are fully permissive to B19 infection. The ability to efficiently generate significant amounts of infectious B19V in cells is useful for the development of killed or attenuated vaccines, therapeutics and efficient diagnostic tools for prevention and treatment of B19V.
Applications:
Advantages:
Method produces pure populations of human erythroid progenitor cells that are fully permissive of B19 infection
Development Status:
Inventors:
Susan Wong (NHLBI)
Neal S Young (NHLBI)
Patent Status:
HHS, Reference No. E-188-2006/0
US, Application No. 12/301,960 filed 21 Nov 2008
PCT, Application No. PCT/US2007/012645 filed 25 May 2007
Relevant Publication:
Collaborative Research Opportunity:
The NHLBI Hematology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize novel methods to produce parvovirus B19 and use as diagnostic or vaccine. Please contact Dr. Neal Young at 301-496-5093, YoungNS@mail.nih.gov for more information.
For Licensing Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220
Ref No: 1475
Updated: 01/2012